Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 68: | Line 68: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
! | ! rowspan="14" |Hematology | ||
! align="center" style="background:#DCDCDC;" + | | ! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders | ||
!Myelodysplastic syndromes | |||
! | ! | ||
| | | | ||
| | | | ||
Line 95: | Line 95: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Aplastic anemia | |||
! | ! | ||
| | | | ||
| | | | ||
Line 132: | Line 130: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Acute leukemia | |||
! | ! | ||
| | | | ||
| | | | ||
Line 159: | Line 155: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |- | ||
!Paroxysmal nocturnal hemoglobinuria (PNH) | |||
! | ! | ||
| | | | ||
| | | | ||
Line 191: | Line 185: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" |'''Thrombotic microangiopathy (TMA)''' | |||
!Thrombotic thrombocytopenic purpura (TTP) | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
|- | |- | ||
!Hemolytic uremic syndrome (HUS) | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ||
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ||
Line 260: | Line 282: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ||
| | | | ||
Line 291: | Line 312: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ||
| | | | ||
Line 322: | Line 342: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ||
| | | | ||
Line 353: | Line 372: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ||
| | | | ||
Line 384: | Line 402: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Alport syndrome | ! align="center" style="background:#DCDCDC;" + |Alport syndrome | ||
| | | | ||
Line 415: | Line 432: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ||
| | | | ||
Line 446: | Line 462: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!'''Nutrient deficiencies''' | |||
!Folate, vitamin B12, copper | |||
|an autoimmune mechanism | |||
! | ! | ||
! | ! | ||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! rowspan="4" |'''Rheumatologic/autoimmune disorders''' | |||
!Immune thrombocytopenia | |||
! | |||
|Antibody-mediated platelet destruction | |||
| | | | ||
| | | | ||
Line 454: | Line 502: | ||
| | | | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + |Moderate to severe | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 478: | Line 525: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Systemic lupus erythematosus (SLE) | |||
! | ! | ||
! | ! | ||
| | | | ||
| | | | ||
Line 510: | Line 556: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Antiphospholipid syndrome (APS) | |||
! | |||
!autoantibody-mediated syndrome | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!Felty's syndrome | |||
! | |||
!splenomegaly | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! rowspan="2" | | |||
! | ! | ||
! | ! | ||
Line 542: | Line 650: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! | ||
! | ! | ||
Line 792: | Line 899: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan=" | ! rowspan="5" |Drug-induced | ||
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia | ! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia | ||
! | ! | ||
Line 958: | Line 1,065: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! rowspan="2" |GI | ||
!Chronic liver disease | |||
| | |||
! | |||
! | ! | ||
| | | | ||
| | | | ||
| | | | ||
Line 1,053: | Line 1,097: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Portal hypertension | |||
! | ! | ||
| | | | ||
| | | | ||
Line 1,085: | Line 1,128: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="3" |Vascular | |||
!Giant capillary hemangioma | |||
! | ! | ||
! | !platelet destruction | ||
! | ! | ||
! | ! | ||
Line 1,179: | Line 1,160: | ||
! | ! | ||
|- | |- | ||
! | !Aortic aneurysm | ||
! | ! | ||
!platelet destruction | |||
! | ! | ||
! | ! | ||
Line 1,210: | Line 1,191: | ||
! | ! | ||
|- | |- | ||
! | !Cardiopulmonary bypass | ||
! | ! | ||
!platelet destruction | |||
! | ! | ||
! | ! | ||
Line 1,241: | Line 1,222: | ||
! | ! | ||
|- | |- | ||
! | ! rowspan="3" |Other | ||
!Alcohol | |||
! | ! | ||
! | ! | ||
Line 1,272: | Line 1,254: | ||
! | ! | ||
|- | |- | ||
! | !Post-transfusion purpura | ||
! | ! | ||
! | !immune-mediated platelet destruction | ||
! | ! | ||
! | ! | ||
Line 1,336: | Line 1,285: | ||
! | ! | ||
|- | |- | ||
!Gestational thrombocytopenia | |||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! |
Revision as of 20:54, 14 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Age range | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | |||||||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||||
Severity | Fever | Bleeding | BP | Splenomegaly | CBC | PBS | Bone marrow exam | |||||||||||||||||||||||
Myelosuppression | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | History | Plt | HB | WBC | PT | PTT | BT | |||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | ||||||||||||||||||||||||||||
Aplastic anemia | ||||||||||||||||||||||||||||||
Acute leukemia | ||||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | Diagnosis of exclusion | |||||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | |||||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | ||||||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | an autoimmune mechanism | ||||||||||||||||||||||||||||
Rheumatologic/autoimmune disorders | Immune thrombocytopenia | Antibody-mediated platelet destruction | Moderate to severe | - | ||||||||||||||||||||||||||
Systemic lupus erythematosus (SLE) | ||||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | |||||||||||||||||||||||||||||
Felty's syndrome | splenomegaly | |||||||||||||||||||||||||||||
Infection-induced | Viral infections | rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||||||||||||||||||||||||||||
HIV |
|
|||||||||||||||||||||||||||||
Bacterial infections | Sepsis | Direct bone marrow suppression | + | |||||||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | |||||||||||||||||||||||||||||
Leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | ||||||||||||||||||||||||||||||
Intracellular parasites | Malaria | |||||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||||
Drug-induced | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | |||||||||||||||||||||||||||
Heparin-induced thrombocytopenia | ||||||||||||||||||||||||||||||
Cytotoxic chemotherapy | ||||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | |||||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||||
GI | Chronic liver disease | Mild | ||||||||||||||||||||||||||||
Portal hypertension | ||||||||||||||||||||||||||||||
Vascular | Giant capillary hemangioma | platelet destruction | ||||||||||||||||||||||||||||
Aortic aneurysm | platelet destruction | |||||||||||||||||||||||||||||
Cardiopulmonary bypass | platelet destruction | |||||||||||||||||||||||||||||
Other | Alcohol | |||||||||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction | |||||||||||||||||||||||||||||
Gestational thrombocytopenia |